As mentioned above, by appropriately applying the interpretation criteria and aberrancy thresholds, no abnormal marker expression is typically present in normal endometrium (whether proliferative or early-, mid-, or late-secretory), or in endometrial polyps, with the exception of PAX2, which can be aberrant in 10–20% of endometrial polyps [43,44]. The gene discussed is PAX2; the disease is endometrial polyp.